Pharmalot.. Pharmalittle.. As the weekend nears.. Catching up on Merck, Roche and..

<img class="size-medium wp-image-977" src="" alt=" pic thx at jake cook on flickr creative commons "width =" 300 "height =" 200 "/>

pic thx at jake cook on flickr creative commons

And so, another week of work will soon be over. Not a moment too soon, yes? This is, as you know, our precious signal for dreaming about weekend projects. Our agenda is extremely modest this time around. We plan to remove the leaves from the Pharmalot campus, walk around with our official mascots and catch up on some work. And you? Large spaces continue to attract. There is still time to plan a getaway. Or you can debate Starbucks coffee mugs. Whatever you do, have a good time. But be safe. See you soon …

The Trans-Pacific Partnership's trade pact could limit the availability of affordable drugs, said World Health Organization Chief Margaret Chan at a conference, ] Reuters . There are "very serious concerns …" If these agreements open up trade but close the door to affordable drugs, we must ask ourselves the question: is this really progress? Member governments have yet to ratify the agreement.

A Federal Court of Appeal upheld an earlier ruling invalidating four of the five patents on the Cubicin antibiotic that Merck acquired with its $ 8.4 billion deal to buy Cubist Pharmaceuticals The Wall Street Journal writes. If the decision is upheld, generic versions may appear in mid-2016, when the remaining patent will expire, and could erase a large portion of Cubicin's sales. The agreement has been trumpeted as a way for Merck to push deeper into antibiotics. Merck can appeal.

Roche plans to close or sell four manufacturing sites and cut about 1,200 jobs in a restructuring program that will cost about $ 1.6 billion over the next five years, Bloomberg News . The drug manufacturing sites are located in Ireland, Spain, Italy and the United States. The drug maker says the new small molecule drugs will require more specialized manufacturing facilities and will be produced in smaller quantities.

Mylan is on the verge of losing his hostile offer to Perrigo The Wall Street Journal reports. A minority of Perrigo shareholders have filed their action in Mylan 's $ 26 billion buyout offer on Thursday night. But Mylan needs at least 50% to take control of his smallest rival, which he has pursued over the past seven months. Perrigo mainly sells branded versions of cold and allergy medications.

China has reported a tougher stance on the quality of drugs by rejecting applications for 11 drugs with inadequate or suspicious clinical data, The Economic Times . This decision follows a call made in July to manufacturers to conduct their own internal investigations of test data, which has already resulted in a number of voluntary reminders.

About one in five patients taking AstraZeneca Brilinta Blood Thinner during trials stopped using the drug because of side effects, according to new research, The News-Journal tells us.

An advisory panel for the FDA will explore the development and licensing of maternal immunizations used to protect babies from disease during a meeting today, MedPage Today says.

<span class = "articleLocatio n"> The FDA approved the expanded use of Harvoni, the hepatitis C drug sold by Gilead Sciences to treating patients with subtypes of the virus and who also have HIV, Reuters writes.

MannKind managed to sell only 13.8 million shares directly to Israeli funds, away from the 50 million shares that the drug maker was hoping for, TheStreet informs us.

Merck buys Harris vaccines, which provide vaccines to breeders, for undisclosed terms, The Des Moines Reports .

A former Bank of New York employee Mellon was sentenced to six months in prison after admitting to have made $ 737,000 in return for tips that a friend of Merck had provided him for pharma mergers, Reuters .

Teva Pharmaceutical's flagship drug, Copaxone, has held up better than expected against a generic last quarter, suggesting that cheaper competitors might not be a disaster, writes Bloomberg News


The State of New York will offer $ 1 million in annual awards for biotech startups as part of a new competition, according to The Albany Business Review .
<img class="WP-PrintIcon" src="" alt=" Print this article "title =" Print this article "style =" border: 0px; "/> Print this article


Leave a Reply